Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma

Background: Moderate-to-severe allergic asthma has a substantial impact on patients’ quality of life (QOL). Despite care consistent with treatment guidelines, many patients with moderate-to-severe asthma still experience variability in asthma control, signaling an unmet need within this population.